Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND1 | P24385 | 8/20 | 0.61 |
| ▸ | CDK4 | P11802 | 4/20 | 0.61 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.61 |
| ▸ | CDK2 | P24941 | 2/20 | 0.61 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.61 |
| ▸ | CDK6 | Q00534 | 8/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | CCND3 | P30281 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 5/20 | 0.44 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.43 |
| ▸ | MLNR | O43193 | 2/20 | 0.43 |
| ▸ | FLT3 | P36888 | 2/20 | 0.42 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.42 |
| ▸ | MERTK | Q12866 | 2/20 | 0.42 |
| ▸ | GAS6 | Q14393 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20744537 | 0.83 | CDK6 (0.58) | CCND1CDK4CDK2CDK6CDK1 | |
| SCHEMBL23296209 | 0.78 | CDK4 (0.58) | CCND1CDK4CCNA2CDK2CCNA1 | |
| SCHEMBL20744557 | 0.78 | CCND1 (0.54) | CCND1CDK4CCNA2CDK2CDK6 | |
| SCHEMBL20038359 | 0.77 | MLNR (0.46) | CCND1CDK4CCNA2CDK2CCNA1 | |
| SCHEMBL20744900 | 0.77 | CNR2 (0.42) | CCND1CDK4CCNA2CDK2CCNA1 | |
| SCHEMBL20750918 | 0.77 | CCND1 (0.42) | CCND1CDK4CCNA2CDK2CCNA1 | |
| SCHEMBL23296205 | 0.76 | CDK6 (0.43) | CCND1CDK4CCNA2CDK2CCNA1 | |
| SCHEMBL29686224 | 0.76 | CCND1 (0.43) | CCND1CDK4CCNA2CDK2CCNA1 | |
| SCHEMBL13535512 | 0.75 | CHRNB2 (0.56) | — | |
| SCHEMBL21414398 | 0.74 | CDK4 (0.48) | CCND1CDK4CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351170-B2 | Substituted pyrimidines as CDK4/6 inhibitors | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351170-B2 | Substituted pyrimidines as CDK4/6 inhibitors | CDK4, CDK6, CDK2 | CCND1 35/4885CDK4 1/4885CCNA2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.